Live Breaking News & Updates on Junshi Bioscienceszhi

Stay updated with breaking news from Junshi bioscienceszhi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Junshi Biosciences Announces Primary Endpoint Met in RENOTORCH Study of Toripalimab for 1st-line Treatment of Advanced Renal Cell Carcinoma

SHANGHAI, China, April 27, 2023 Shanghai Junshi Biosciences Co., Ltd , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of. | April 27, 2023 ....

United States , United Kingdom , San Francisco , Zhi Li , Junshi Bioscience , Junshi Biosciences , Radiographic Review Committee , Shanghai Junshi Biosciences Co Ltd , Ir Team , University Cancer Hospital , Drug Administration , Regulatory Agency , International Metastatic Renal Cell Carcinoma Database Consortium , Data Monitoring Committee , Pr Team , National Reimbursement Drug List , Global Research , European Medicines Agency , Independent Data Monitoring Committee , Chinese Medical Journal , Development President , Independent Radiographic Review Committee , Professor Jun , Peking University Cancer Hospital , Professor Yiran , Renji Hospital ,

Junshi Biosciences Announces Toripalimab plus Chemotherapy Significantly Improved Event-free Survival (EFS) versus Chemotherapy as Perioperative Treatment for Resectable Stage III Non-small Cell Lung Cancer (NSCLC) in Phase 3 Neotorch Study

Perioperative toripalimab plus chemotherapy significantly improved EFS and reduced risk of disease recurrence, progression events or death by 60% among resectable stage III NSCLC patients, compared to ....

United Kingdom , United States , Junshi Biosciences , Junshi Bioscience , Zhi Li , Pr Team , National Reimbursement Drug List , European Medicines Agency , Ir Team , Drug Administration , Shanghai Junshi Biosciences Co Ltd , Regulatory Agency , Neotorch Study , Southeast Asia , Biologics License Application , Breakthrough Therapy , Fast Track , Orphan Drug , Emergency Use Authorizations ,

Legend Capital: Rxilient Biotech and Junshi Biosciences form Joint Venture to develop and commercialize Toripalimab in Southeast Asia

HONG KONG, Mar 31, 2023 - (ACN Newswire) - On 28th March 2023, Rxilient Biotech (a portfolio company of Legend Capital) and Junshi Biosciences made a joint announcement that two parties will form a joint ....

Republic Of , United States , United Kingdom , Chong Tan , Junshi Biosciences , Xiong Jun , China Medical System Holdings Limited , Rxilient Biotech , Legend Capital , Managing Director , Executive Director , Chief Executive , Lam Kong , Lee Ker , Southeast Asia , Southeast Asian ,

Junshi Biosciences Announces 2022 Full Year Financial Results and Provides Corporate Updates

SHANGHAI, China, March 31, 2023 Shanghai Junshi Biosciences Co., Ltd , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of. | March 31, 2023 ....

United Arab Emirates , United States , Saudi Arabia , San Francisco , Kingdom Of Saudi Arabia , Zhi Li , Acta Pharmacologica Sinica , Junshi Biosciences , Junshi Bioscience , Shanghai Junshi Biosciences Co Ltd , Coherus Biosciences Inc , Pr Team , Sun Yat Sen University Cancer Center , Wigen Biomedicine Technology Shanghai Co Ltd , National Medical Products Administration Of China , Drug Administration , Market Of The Shanghai Stock Exchange On , European Medicines Agency , Risen Suzhou Biosciences Co Ltd , Ir Team , Shanghai Lingang Production , Shanghai Stock Exchange , National Medical Products Administration , United States Food , Signal Transduction , Targeted Therapy ,

China 2022 National Reimbursement Drug List Drug Pricing

China National Healthcare Security Administration NHSA published 2022 National Reimbursement Drug List 2022 NRDL, implementing comparable level of pricing discounts to those seen in 2021. Out of 147 drugs negotiated, 121 were successfully added to 2022 NRDL, including 91 exclusive. ....

Novartis Kesimpta , Abbvie Venclexta , Brii Bioscience Amubarvimab , Takeda Vpriv , Takeda Alunbrigtm , Roche Sylvant , Junsi Biosciences , Takeda Takhzyro , Novartis Zolgensma , Henlius Serplulimab , Takeda Alglucosidase , Roche Risdiplam , Cstone Pharmaceuticals , National Health Commission , China National Healthcare Security Administration , National Reimbursement Drug List , National Medical Products Administration , National Healthcare Security Administration , Insurance Resource Spending At National Level , National Medical Insurance , Reimbursement Drug List , Effective Date , Consistent Price Cut , Medical Insurance Resource Spending , Genuine Biotech , Although Simnotrelvir ,